Sacha Mann

Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks that allow the tumor to subvert the immune system. We are advancing our first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, our target discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC’s innovations in precision protein editing therapies target genetically defined diseases. A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within. We have a bigger, bolder vision for genomic medicine: treatments as versatile, precise, and far-reaching as the body’s own cells. Our team takes inspired action towards pushing beyond today’s possible with the goal of delivering a one-time, off-the-shelf treatment to patients everywhere.

Ribon is a clinical-stage biotechnology company dedicated to the discovery and development of first-in-class small molecule inhibitors to block the fundamental ability of cancer cells to survive under stress.

Didadem Biotherapeutics is pioneering the development of first-in-class engineered exosomes to treat auto-immune conditions and cancers.

Prescryptive is a healthcare technology company transforming the U.S. prescription drug market. We connect healthcare participants in a new ecosystem that puts consumers first and gives them digital control over their prescriptions – where health outcomes begin. The core infrastructure we provide creates a trusted pharmacy marketplace, empowers consumers to control their care, and unlocks healthcare innovation through partnership. Co-founded in 2017 by Microsoft cloud veterans, Prescryptive is rewriting the script to help everyone make better healthcare decisions.

Blue Mesa Health delivers preventive health and wellness digitally. Chronic diseases such as diabetes, cardiovascular disease, and obesity are affecting an increasing number of Americans. We provide chronic disease prevention coaching, with an emphasis on behavior modification, delivered remotely and digitally through an innovative model that combines a human health coach, a wireless scale, and a software service available on the web and mobile.

Msi Methylation Sciences INC is a pharmaceuticals company based out of 4475 Wayburne Dr, Burnaby, British Columbia, Canada.

Atonomics is a diagnostics company that designs immunoassay systems for the IVD industry.

Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks that allow the tumor to subvert the immune system. We are advancing our first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, our target discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer. We believe that transformational discoveries are found at the interface between disciplines. With a proven track record of drug discovery and development, our team is passionate about solving hard problems and driven to deliver new medicines to cancer patients with significant unmet needs. At Larkspur, we grow together, building a culture that highly values joy, trust, and courage.

hC Bioscience is dedicated to improving the lives of patients with the development of first-in-class tRNA-based therapeutics targeting protein dysfunction. hC’s innovations in precision protein editing therapies target genetically defined diseases. A single tRNA therapy has the potential to treat many diseases, regardless of the gene or location of the mutation.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.